RYTHMODAN

This brand name is authorized in Australia, Canada, France, Japan, Malta, New Zealand, United Kingdom, South Africa

Active ingredients

The drug RYTHMODAN contains one active pharmaceutical ingredient (API):

1 Disopyramide UNII GFO928U8MQ - DISOPYRAMIDE

Disopyramide is a myocardial depressant and has anti-cholinergic effects. It decreases membrane responsiveness, prolongs the effective refractory period (ERP) and slows automaticity in cells with augmented automaticity. Read about Disopyramide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
Rythmodan 100mg Capsules	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC
RYTHMODAN Capsules	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C01BA03	Disopyramide	C Cardiovascular system → C01 Cardiac therapy → C01B Antiarrhythmics, class I and III → C01BA Antiarrhythmics, class Ia
Discover more medicines within C01BA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2923W
Country: CA	Health Products and Food Branch	Identifier(s): 02224801
Country: FR	Base de données publique des médicaments	Identifier(s): 63063487, 69235837
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 158597, 34655
Country: JP	医薬品医療機器総合機構	Identifier(s): 2129002M1060, 2129002M2139, 2129005F1129, 2129401A1070
Country: MT	Medicines Authority	Identifier(s): AA565/29302
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 1702
Country: ZA	Health Products Regulatory Authority	Identifier(s): E/6.2/163